The selective therapeutic apheresis procedures

Journal of Clinical Apheresis

Volumn 28, Issue 1, 2013, Pages 20-29

  Sanchez, Amber P ^a,d   Cunard, Robyn ^a,b   Ward, David M ^a,c,d  

^a UCSD MEDICAL CENTER   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

adsorption resins; DFPP; extracorporeal photopheresis; HELP; immunoadsorption; LDL apheresis; leukocyte apheresis; selective apheresis

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR; COMPLEMENT COMPONENT C1Q; DEXTRAN SULFATE; EPITOPE; IMMOBILIZED ANTIBODY; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN; METHOXSALEN; POLYCLONAL ANTIBODY; STAPHYLOCOCCUS PROTEIN A;

APHERESIS; CONFERENCE PAPER; CONTINUOUS HEMODIAFILTRATION; CRYOFILTRATION; CRYOGLOBULINEMIA; CUTANEOUS T CELL LYMPHOMA; DOUBLE FILTRATION PLASMAPHERESIS; FAMILIAL HYPERCHOLESTEROLEMIA; GRAFT VERSUS HOST REACTION; HEMOPERFUSION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOADSORPTION; LEUKAPHERESIS; NONHUMAN; PHOTOCHEMOTHERAPY; PLASMA VISCOSITY; PLASMA VOLUME; PLASMAPHERESIS; PUVA; WALDENSTROEM MACROGLOBULINEMIA;

AUTOANTIBODIES; BLOOD CELLS; BLOOD COMPONENT REMOVAL; CRYOGLOBULINS; FILTRATION; HUMANS; IMMOBILIZED PROTEINS; IMMUNOGLOBULINS; IMMUNOSORBENT TECHNIQUES; LIPIDS; LIPOPROTEINS; PHOTOPHERESIS; RESINS, SYNTHETIC; STAPHYLOCOCCAL PROTEIN A; UNITED STATES;

EID: 84874040945     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21265     Document Type: Conference Paper

References (88)

1. Balogun RA, Ogunniyi A, Sanford K, Okafor C, Lobo PI, Siami G, Barcia J, and, Kaplan AA,. Therapeutic apheresis in special populations. J Clin Apher 2010; 25: 265-274.
2. Stamler J, Wentworth D, Neaton JD,. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 1986; 256: 2823-2828.
3. Winters JL,. Lipid apheresis, indications, and principles. J Clin Apher 2011; 26: 269-275.
4. Bambauer R, Bambauer C, Lehmann B, Latza R, and, Schiel R,. LDL-apheresis: technical and clinical aspects. Sci World J 2012;2 012: 314283.
5. Wehrli G,. Therapeutic apheresis instrumentation. J Clin Apher 2011; 26: 286-290.
6. Kroon AA, Aengevaeren WR, van der, Werf T, Uijen GJ, Reiber JH, Bruschke AV, and, Stalenhoef AF,. LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826-1835.
7. Suckfull M,. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 2002; 360: 1811-1817.
8. Bosch T,. Recent advances in therapeutic apheresis. J Artif Organs 2003; 6: 1-8.
9. Koll RA,. LDL-Therasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Therap Apher Off J Int Soc Apher Jpn Soc Apher 1998; 2: 142-146.
10. Bosch T,. Therapeutic apheresis-state of the art in the year 2005. Therap Apher Dialysis 2005; 9: 459-468.
11. Bosch T, Thiery J, Gurland HJ, and, Seidel D,. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholesterolaemia and end-stage renal failure. Nephrol Dialy Transplant 1993; 8: 1350-1358.
12. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, and, Parhofer KG,. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003; 27: 1116-1122.
13. Momiyama T, Hiranaka T, Nomura F, Tominaga H, and, Nishioka T,. Coronary artery bypass grafting for left main trunk coronary artery lesion associated with essential thrombocythemia. Clin Cardiol 1993; 16: 691-693.
14. Stefanutti C, Vivenzio A, Di, Giacomo S, Mazzarella B, Ferraro PM, and, Abbolito S,. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfusion Apher Sci 2010; 42: 21-26.
15. Ward DM,. Conventional apheresis therapies: a review. J Clin Apher 2011; 26: 230-238.
16. Siami GA, Siami FS,. Membrane plasmapheresis in the United States: a review over the last 20 years. Therap Apher 2001; 5: 315-320.
17. Namba T, Shiba R, Yamamoto T, Hirai Y, Moriwaki T, Matsuda J, Kadoya H, Takeji M, Yamada Y, Yoshihara H,. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol 2010; 14: 372-376.
18. Valbonesi M, Montani F, Guzzini F, Angelini G, and, Florio G,. Efficacy of discontinuous flow centrifugation compared with cascade filtration in Waldenstrom's macroglobulinemia: a pilot study. Int J Artif Organs 1985; 8: 165-168.
19. Agishi T, Kaneko I, Hasuo Y, Hayasaka Y, Sanaka T, Ota K, Amemiya H, Sugino N, Abe M, Ono T,. Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs 1980; 26: 406-411.
20. Klingel R, Fassbender C, Fassbender T, Erdtracht B, and, Berrouschot J,. Rheopheresis: rheologic, functional, and structural aspects. Therap Apher 2000; 4: 348-357.
21. Krakauer RS, Wysenbeek AJ, Wallace DJ, Jones JV, Smith JW, Malchesky P, Greenstreet R, Goldfinger D, Klinenberg JR, McLeod B,. Therapeutic trial of cryofiltration in patients with rheumatoid arthritis. Am J Med 1983; 74: 951-955.
22. Malchesky PS, Smith JW, Koo A, Clough J, Skibinski C, Beck GJ, and, Nose Y,. Uncontrolled trial of cryofiltration in rheumatoid arthritis. J Clin Apher 1988; 4: 158-165.
23. Katsume C, Abe Y, Horiuchi T, Matsubara S, Ueno M, Matsugane T, Blasutig E, Smith JW, Malchesky PS, and, Nose Y,. Cryogel studies for the optimization of cryofiltration (CF) therapy. Trans Am Soc Artif Intern Organs 1983; 29: 463-467.
24. Siami FS, Siami GA,. Cryofiltration apheresis in the treatment of cryoprecipitate induced diseases. Ther Apher 1997; 1: 58-62.
25. Rockx MA, Clark WF,. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 42: 247-251.
26. Siami FS, Siami GA,. A last resort modality using cryofiltration apheresis for the treatment of cold hemagglutinin disease in a Veterans Administration hospital. Ther Apher Dial 2004; 8: 398-403.
27. Ohkawara T, Saito M, Nakagawa S, Ohizumi H, Tamaki T, Yonekawa M, Takeda H, Asaka M, Nishihira J, and, Kawamura A,. A case report of the therapeutic effect of cryofiltration in a patient with glucocorticoid-resistant ulcerative colitis. Ther Apher Dial 2007; 11: 159-162.
28. Sinha D, Lambie M, Krishnan N, McSorley K, Hamer R, Lowe D, Briggs D, Fletcher S, Zehnder D, and, Higgins RM,. Cryofiltration in the treatment of cryoglobulinemia and HLA antibody-incompatible transplantation. Ther Apher Dial 2012; 16: 91-96.
29. Siami GA, Siami FS,. Current topics on cryofiltration technologies. Ther Apher 2001; 5: 283-286.
30. Siami GA, Wilkins W, Stone WJ, Koo AP, and, Zborowski M,. Clinical trials of a cryoglobulin filter. Asaio J 1994; 40: M658-M662.
31. Kawamura A, Yonekawa M, Takahashi M, Meguro J, Yanagida N, Kurauchi N, Ikeda A, Kukita K, and, Sakashita E,. Reduction of EDA(+) fibronectin and its clinical importance on cryofiltration. Int J Artif Organs 1994; 17: 559-564.
32. Smith JW, Abe Y, Katsume C, Malchesky PS, and, Nose Y,. Membrane plasmapheresis with plasma cryofiltration: characterization of cryogel and clinical response. Life Support Syst 1983;(Suppl 1): 439-442.
33. Wilpert J, Geyer M, Teschner S, Schaefer T, Pisarski P, Schulz-Huotari C, Gropp A, Wisniewski U, Goebel H, Gerke P,. ABO-incompatible kidney transplantation-proposal of an intensified apheresis strategy for patients with high initial isoagglutinine titers. J Clin Apher 2007; 22: 314-322.
34. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S, Neumayer HH, Wernecke KD,. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590-1598.
35. Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jimenez-Boj E, Horl WH, Graninger WB, and, Derfler K,. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005; 64: 1015-1021.
36. Zeitler H, Ulrich-Merzenich G, Hoffmann L, Kornblum C, Schmidt S, Vetter H, and, Walger P,. Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis. Artif Organs 2006; 30: 597-605.
37. Teschner S, Stippel D, Grunenberg R, Beck B, Wahba R, Gathof B, Benzing T, and, Burst V,. ABO-incompatible kidney transplantation using regenerative selective immunoglobulin adsorption. J Clin Apher 2012; 27: 51-60.
38. Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K, Wallukat G, Wernecke KD, Stangl K, Baumann G,. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001; 103: 2681-2686.
39. Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, Wallukat G, Wernecke KD, Baumann G, and, Stangl K,. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39: 646-652.
40. Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, Deal C, Evans S, Fleischmann R, Gendreau RM,. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheumat 1999; 42: 2153-2159.
41. Gendreau RM,. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Therap Apher 2001; 5: 79-83.
42. Goodyear CS, Silverman GJ,. Death by a B cell superantigen: in vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal toxin. J Exp Med 2003; 197: 1125-1139.
43. Sasso EH, Merrill C, Furst TE,. Immunoglobulin binding properties of the Prosorba immunadsorption column in treatment of rheumatoid arthritis. Therap Apher 2001; 5: 84-91.
44. Terman DS, Durante D, Buffaloe G, and, McIntosh R,. Attenuation of canine nephrotoxic glomerulonephritis with an extracorporeal immunoadsorbent. Scand J Immunol 1977; 6: 195-202.
45. Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, and, Ayus JC,. Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet 1979; 2: 824-827.
46. Wallukat G, Reinke P, Dorffel WV, Luther HP, Bestvater K, Felix SB, and, Baumann G,. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 1996; 54: 191-195.
47. Dorffel WV, Wallukat G, Dorffel Y, Felix SB, and, Baumann G,. Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up. Int J Cardiol 2004; 97: 529-534.
48. Dandel M, Wallukat G, Potapov E, and, Hetzer R,. Role of beta(1)-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology 2012; 217: 511-520.
49. Winters JL,. Apheresis in the treatment of idiopathic dilated cardiomyopathy. J Clin Apher 2012.
50. Ronspeck W, Brinckmann R, Egner R, Gebauer F, Winkler D, Jekow P, Wallukat G, Muller J, and, Kunze R,. Peptide based adsorbers for therapeutic immunoadsorption. Therap Apher Dialysis 2003; 7: 91-97.
51. Tyden G, Kumlien G, Fehrman I,. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730-731.
52. Kumlien G, Ullstrom L, Losvall A, Persson LG, and, Tyden G,. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion 2006; 46: 1568-1575.
53. Troisi R, Noens L, Montalti R, Ricciardi S, Philippe J, Praet M, Conoscitore P, Centra M, and de, Hemptinne B,. ABO-mismatch adult living donor liver transplantation using antigen-specific immunoadsorption and quadruple immunosuppression without splenectomy. Liver Transpl 2006; 12: 1412-1417.
54. Genberg H, Kumlien G, Wennberg L, and, Tyden G,. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dialysis Transpl 2011; 26: 2394-2400.
55. Berner B, Scheel AK, Schettler V, Hummel KM, Reuss-Borst MA, Muller GA, Oestmann E, Leinenbach HP, and, Hepper M,. Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption. Ann Rheum Dis 2001; 60: 898-899.
56. Pfueller B, Wolbart K, Bruns A, Burmester GR, and, Hiepe F,. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001; 44: 1962-1963.
57. Braun N, Bosch T,. Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 2000; 9: 2017-2038.
58. Yoshida M, Tamura Y, Yamada Y, Yamawaki N, and, Yamashita Y,. Immusorba TR and Immusorba PH: basics of design and features of functions. Therap Apher 1998; 2: 185-192.
59. Hirata N, Kuriyama T, Yamawaki N,. Immusorba TR and PH. Therap Apher Dialysis 2003; 7: 85-90.
60. Braun N, Junger M, Klein R, Gutenberger S, Guagnin M, and, Risler T,. Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus. Therap Apher 2002; 6: 471-477.
61. Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, Kawakami M, Nakamura H, Yabuki T, Kutsuki H,. Evaluation of adsorption selectivity dextran sulfate bound cellulose beads for the removal of anti-DNA antibodies. Therap Apher 1999; 3: 75-80.
62. Kamijo Y, Kaneko Y, Ichikawa T, Kobayashi N, Koyama T, Kakegawa T, Kamijo H, Kono K, Minami S, Tanaka N, et al. A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis. Therap Apher 2002; 6: 459-462.
63. Julius U, Tselmin S, Fischer S, Passauer J, and, Bornstein SR,. The Dresden apheresis center-experience with LDL apheresis and immunoadsorption. Atheroscl Suppl 2009; 10: 12-16.
64. Stegmayr B, Abdel-Rahman EM, Balogun RA,. Septic shock with multiorgan failure: from conventional apheresis to adsorption therapies. Semin Dialysis 2012; 25: 171-175.
65. Bellomo R, Tetta C, Brendolan A, and, Ronco C,. Coupled plasma filtration adsorption. Blood Purif 2002; 20: 289-292.
66. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De, Sutter JH, and, Lameire NH,. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846-853.
67. Bellomo R, Tetta C, Ronco C,. Coupled plasma filtration adsorption. Intensive Care Med 2003; 29: 1222-1228.
68. Nagaki M, Hughes RD, Keane HM, Lau JY, and, Williams R,. In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circ Shock 1992; 38: 182-188.
69. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La, Greca G, Inguaggiato P,. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002; 30: 1250-1255.
70. Formica M, Olivieri C, Livigni S, Cesano G, Vallero A, Maio M, and, Tetta C,. Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock. Intensive Care Med 2003; 29: 703-708.
71. Hu D, Sun S, Zhu B, Mei Z, Wang L, Zhu S, and, Zhao W,. Effects of coupled plasma filtration adsorption on septic patients with multiple organ dysfunction syndrome. Ren Fail 34: 834-839.
72. Mao HJ, Scarrone S, Pizzi B, Bonato V, and, Vivaldi N,. Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome. Int J Artif Organs 2009; 32: 31-38.
73. Moretti R, Yu S, Yu XB, Zhang B, Zhang L, Xu XR, Wang XY, and, Xing CY,. Coupled plasma filtration-adsorption in Weil's syndrome: case report. Minerva Anestesiol 2011; 77: 846-849.
74. Lentini P, Cruz D, Nalesso F, de, Cal M, Bobek I, Garzotto F, Zanella M, Brendolan A, Piccinni P, and, Ronco C,. A pilot study comparing pulse high volume hemofiltration (pHVHF) and coupled plasma filtration adsorption (CPFA) in septic shock patients. G Ital Nefrol 2009; 26: 695-703.
75. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G,. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303.
76. Ward DM,. Extracorporeal photopheresis: how, when, and why. J Clin Apher 2011; 26: 276-285.
77. Reinisch W, Knobler R, Rutgeerts PJ, Ochsenkuhn T, Anderson F, von, Tirpitz C, Kaatz M, van der, Woude CJ, Parenti D, and, Mannon PJ,. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: An open-label, multicenter, prospective trial. Inflammatory Bowel Dis 2012.
78. Schooneman F,. Extracorporeal photopheresis technical aspects. Trans Apher Sci 2003; 28: 51-61.
79. Hillen U, Meyer S, Schadendorf D, and, Kremens B,. Photopheresis in pediatric patients with low-body weight using the UVAR XTS system. J German Soc Dermatol 2010; 8: 32-37.
80. Schneiderman J, Jacobsohn DA, Collins J, Thormann K, and, Kletzel M,. The use of fluid boluses to safely perform extracorporeal photopheresis (ECP) in low-weight children: a novel procedure. J Clin Apher 2010; 25: 63-69.
81. Andreu G, Leon A, Heshmati F, Tod M, Menkes CJ, Baudelot J, and, Laroche L,. Extracorporeal photochemotherapy: evaluation of two techniques and use in connective tissue disorders. Transf Sci 1994; 15: 443-454.
82. Perotti C, Torretta L, Viarengo G, Roveda L, Bernuzzi S, Carbone S, Del, Fante C, La, Torre R, Locatelli F, Bonetti F,. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica 1999; 84: 237-241.
83. Perseghin P, Incontri A,. Mononuclear cell collection in patients treated with extracorporeal photochemotherapy by using the off-line method: a comparison between COBE Spectra AutoPbsc version 6.1 and Amicus cell separators. J Clin Apher 2010; 25: 310-314.
84. Vernia P, D'Ovidio V, Meo D,. Leukocytapheresis in the treatment of inflammatory bowel disease: current position and perspectives. Transf Apher Sci 2010; 43: 227-229.
85. Nishise S, Takeda Y, Nishise Y, Fujishima S, Orii T, Otake S, Sato T, Sasaki Y, Takeda H, and, Kawata S,. Biological effect of anaphylatoxin C5a on the generation of anti-inflammatory substances in leukocyte adsorption. Therap Apher Dialysis 2009; 13: 509-514.
86. Yoshino T, Nakase H, Matsuura M, Matsumura K, Honzawa Y, Fukuchi T, Watanabe K, Murano M, Tsujikawa T, Fukunaga K,. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion 2011; 84: 3-9.
87. Muratov V, Paulsson JM, Elvin K, Lofberg R, and, Lundahl J,. Kinetics of the soluble IL-1 receptor type I during treatment with an LCAP filter in patients with inflammatory bowel disease. J Clin Apher 2012; 27: 61-63.
88. Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, and, Lofberg R,. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011; 163: 50-58.